Pathophysiological role of ion channels and transporters in HER2-positive breast cancer

被引：2

作者：

Zhou, Zhengxing ^{[1
]}

Zhang, Chengmin ^{[1
]}

Ma, Zhiyuan ^{[2
]}

Wang, Hu ^{[1
]}

Tuo, Biguang ^{[2
]}

Cheng, Xiaoming ^{[1
]}

Liu, Xuemei ^{[2
]}

Li, Taolang ^{[1
]}

机构：

[1] Zunyi Med Univ, Affiliated Hosp, Dept Thyroid & Breast Surg, Zunyi 563003, Guizhou, Peoples R China

[2] Zunyi Med Univ, Affiliated Hosp, Dept Gastroenterol, Zunyi 563003, Guizhou, Peoples R China

来源：

CANCER GENE THERAPY | 2022年 / 29卷 / 8-9期

基金：

中国国家自然科学基金;

关键词：

MAMMARY-TUMOR GROWTH; COTRANSPORTER NBCN1; SIGNAL-TRANSDUCTION; PROGNOSTIC MARKER; ACTIVITY PROMOTES; EXPRESSION; CELLS; RECEPTOR; PROTEIN; HER2;

D O I：

10.1038/s41417-021-00407-4

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The incidence of breast cancer (BC) has been increasing each year, and BC is now the most common malignant tumor in women. Among the numerous BC subtypes, HER2-positive BC can be treated with a variety of strategies based on targeting HER2. Although there has been great progress in the treatment of HER2-positive BC, recurrence, metastasis and drug resistance remain considerable challenges. The dysfunction of ion channels and transporters can affect the development and progression of HER2-positive BC, so these entities are expected to be new therapeutic targets. This review summarizes various ion channels and transporters associated with HER2-positive BC and suggests potential targets for the development of new and effective therapies.

引用

页码：1097 / 1104

页数：8

共 50 条

[31] Treatment strategy for HER2-positive breast cancer
Hirofumi Mukai
International Journal of Clinical Oncology, 2010, 15 : 335 - 340
[32] Personalized medicine for HER2-positive breast cancer
Wang, Zhixiang
BREAST CANCER MANAGEMENT, 2015, 4 (05) : 237 - 240
[33] Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer
Yamaguchi, Takeshi
Mukai, Hirofumi
Yamashita, Satoshi
Fujii, Satoshi
Ushijima, Toshikazu
ONCOLOGY, 2015, 88 (06) : 377 - 384
[34] The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
Griffin, Nathan
Marsland, Mark
Roselli, Severine
Oldmeadow, Christopher
Attia, John
Walker, Marjorie M.
Hondermarck, Hubert
Faulkner, Sam
BIOMOLECULES, 2020, 10 (09) : 1 - 13
[35] Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
Dempsey, Naomi
Sandoval, Ana
Mahtani, Reshma
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (09) : 1120 - 1137
[36] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
Mariani, Gabriella
Fasolo, Angelica
De Benedictis, Elena
Gianni, Luca
NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 93 - 104
[37] PTEN mutations prevalence in HER2-positive breast cancer patients
Elwy, Fatma
El Din, Zeinab Shehab
Assem, Magda M.
Hassan, Nagwa H. A.
Helwa, Reham
REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2023, 36 (01):
[38] Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer
Melichar, Bohuslav
Studentova, Hana
Kalabova, Hana
Vitaskova, Denisa
IMMUNOTHERAPY, 2014, 6 (07) : 811 - 819
[39] Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer
Gao, Chundi
Zhuang, Jing
Li, Huayao
Liu, Cun
Zhou, Chao
Liu, Lijuan
Feng, Fubin
Sun, Changgang
Wu, Jibiao
CANCER CELL INTERNATIONAL, 2020, 20 (01)
[40] Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape
Huang, Lingli
Liu, Xin
Li, Li
Wang, Lei
Wu, Nan
Liu, Zhixian
MEDICAL ONCOLOGY, 2022, 39 (05)

← 1 2 3 4 5 →